Biotech companies are increasingly turning to digital coins and cryptocurrency strategies in an effort to revive struggling stock prices and attract investor attention. This shift comes amid a challenging period for the biotech sector, with industry indices notably lagging behind broader markets and funding prospects dimming.

In 2025, a noticeable trend has emerged: over ten biotech firms have announced plans to establish crypto treasuries, often resulting in dramatic—yet short-lived—stock price surges. For example, 180 Life Sciences Corp., now known as ETHZilla, saw its shares triple after revealing a significant Ether token acquisition. However, those gains evaporated within weeks. Similarly, Sonnet BioTherapeutics Holdings experienced a single-day jump of more than 240% following its crypto pivot announcement, and MEI Pharma temporarily doubled in value after unveiling a Litecoin-centric funding strategy.

These moves reflect the sector’s search for alternative pathways as traditional fundraising stalls. With high interest rates and fewer IPOs, biotech leaders are embracing the volatility and visibility that crypto assets can offer, attempting to reposition themselves in the eyes of investors.

The drive into digital assets isn’t limited to biotechnology alone. Small medical firms are also exploring substantial investments in cryptocurrencies. Sharps Technology recently announced plans to raise $400 million via stock sales to create one of the largest corporate Solana treasuries, positioning itself as a leader in this unconventional financial strategy.

While these crypto tie-ins spark short-term excitement, their long-term effectiveness in stabilizing or growing stock values remains uncertain. Many industry observers question whether the allure of digital assets can truly revitalize struggling biotechs or if these bold pivots are merely temporary boosts driven by market hype.

As the biotech sector continues to adapt to financial headwinds, the intersection of life sciences and digital currency will be one to watch—whether it’s a passing fad or a lasting innovation in corporate strategy.